Chardan lowered the firm’s price target on uniQure (QURE) to $16 from $53 and keeps a Buy rating on the shares after the company held a Type A meeting resulted in what the firm calls the “worst-case regulatory scenario” for AMT-130 in Huntington’s disease. While the firm maintains its position that the three-year AMT-130 data reported last year “strongly support the drug’s benefit in HD,” it says that even with a smaller new trial uniQure would likely need three-plus years to generate data.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- FDA review process for accelerated approval narrows, less predictable, WSJ says
- uniQure: Regulatory Setback on AMT-130 Seen as Surmountable, Supporting Buy Rating on Undervalued Long-Term Pipeline Upside
- uniQure price target lowered to $9 from $37 at Goldman Sachs
- uniQure downgraded to Neutral from Outperform at Mizuho
- uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments